Immunic, Inc.
$0.95
▲
0.87%
2026-04-21 07:30:00
imux.com
NCM: IMUX
Explore Immunic, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$124.59 M
Current Price
$0.95
52W High / Low
$1.51 / $0.51
Stock P/E
—
Book Value
$-0.06
Dividend Yield
—
ROCE
1572.16%
ROE
-16.53%
Face Value
—
EPS
$-0.62
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
92
Beta
1.37
Debt / Equity
-0.09
Current Ratio
0.75
Quick Ratio
0.75
Forward P/E
-3.37
Price / Sales
—
Enterprise Value
$137.74 M
EV / EBITDA
-1.34
EV / Revenue
—
Rating
None
Target Price
$5.25
EPS Forecast (FY)
—
Pros
- Efficient use of capital employed.
- Balance sheet leverage appears manageable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Current ratio suggests tighter short-term liquidity.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Lexeo Therapeutics, Inc. | $6.53 | — | $511.94 M | — | -85.23% | -55% | $10.99 / $2.19 | $3.38 |
| 2. | Cogent Biosciences, Inc. | $37 | — | $6.05 B | — | -38.16% | -73.7% | $43.73 / $4.12 | $3.4 |
| 3. | NeOnc Technologies Holdings, Inc. | $5.17 | — | $133.03 M | — | 129% | 122.08% | $12.99 / $3.2 | $-0.81 |
| 4. | Day One Biopharmaceuticals, Inc. | $21.48 | — | $2.22 B | — | -28.56% | -22.74% | $21.49 / $5.63 | $4.28 |
| 5. | Iovance Biotherapeutics, Inc. | $3.78 | — | $1.56 B | — | -51.39% | -55.5% | $5.63 / $1.64 | $1.7 |
| 6. | HCW Biologics Inc. | $0.41 | — | $2.94 M | — | -4764.31% | -897.37% | $17.8 / $0.25 | $-0.8 |
| 7. | Minerva Neurosciences, Inc. | $6.89 | — | $289.51 M | — | -15.79% | 352.58% | $12.46 / $1.3 | $-3.25 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -23.33 M | -25.99 M | -27.08 M | -26.82 M | -25.63 M | — |
| Net Profit | -19.3 M | -25.58 M | -26.82 M | -25.47 M | -25.18 M | — |
| EPS in Rs | -0.15 | -0.2 | -0.21 | -0.2 | -0.19 | -0.24 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -103.23 M | -98.05 M | -99.22 M | -86.52 M |
| Net Profit | -97.17 M | -100.51 M | -93.61 M | -120.41 M |
| EPS in Rs | -0.74 | -0.77 | -0.72 | -0.92 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 24.05 M | 40.87 M | 54.3 M | 127.75 M |
| Total Liabilities | 30.73 M | 22.44 M | 25.37 M | 14.07 M |
| Equity | -6.67 M | 18.43 M | 28.93 M | 113.68 M |
| Current Assets | 22.87 M | 39.33 M | 52.53 M | 125.86 M |
| Current Liabilities | 30.62 M | 22.18 M | 24.73 M | 13.08 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -85.81 M | -84.77 M | -70.83 M | -65.14 M |
| Investing CF | -0.16 M | -0.26 M | 9.46 M | -9.74 M |
| Financing CF | 65.58 M | 74.54 M | 1.03 M | 95.76 M |
| Free CF | -85.97 M | -85.03 M | -71.16 M | -65.26 M |
| Capex | -0.16 M | -0.26 M | -0.33 M | -0.11 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -7.37% | 22.25% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.